NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 12 percent, mostly due to a 16 percent increase in revenues from its non-invasive heart transplant rejection test AlloMap.

For the three months ended June 30, the firm reported total revenues of $12.0 million, up from $10.7 million in Q2 2016, and beating the average Wall Street estimate for revenues of $11.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.